loading
Biomarin Pharmaceutical Inc stock is traded at $58.58, with a volume of 1.65M. It is up +0.88% in the last 24 hours and down -1.05% over the past month. BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
See More
Previous Close:
$58.07
Open:
$58.23
24h Volume:
1.65M
Relative Volume:
0.73
Market Cap:
$11.25B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
21.78
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
+1.81%
1M Performance:
-1.05%
6M Performance:
-14.17%
1Y Performance:
-34.93%
1-Day Range:
Value
$57.74
$58.85
1-Week Range:
Value
$57.16
$58.85
52-Week Range:
Value
$52.93
$93.04

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
Name
Biomarin Pharmaceutical Inc
Name
Phone
(415) 506-6700
Name
Address
105 DIGITAL DRIVE, NOVATO, CA
Name
Employee
3,040
Name
Twitter
Name
Next Earnings Date
2024-10-29
Name
Latest SEC Filings
Name
BMRN's Discussions on Twitter

Compare BMRN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
58.58 11.03B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-03-25 Resumed Morgan Stanley Overweight
Feb-24-25 Upgrade Oppenheimer Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Oct-30-24 Downgrade William Blair Outperform → Mkt Perform
Oct-10-24 Resumed Raymond James Outperform
Aug-20-24 Upgrade Bernstein Mkt Perform → Outperform
May-17-24 Downgrade Robert W. Baird Outperform → Neutral
May-14-24 Initiated Evercore ISI Outperform
Nov-15-23 Initiated Wells Fargo Overweight
Oct-23-23 Upgrade Bernstein Underperform → Mkt Perform
Sep-28-23 Initiated Raymond James Mkt Perform
Sep-18-23 Initiated UBS Buy
Jul-27-23 Initiated Scotiabank Sector Perform
Jul-05-23 Upgrade BMO Capital Markets Market Perform → Outperform
Jun-14-23 Resumed Credit Suisse Outperform
Mar-21-23 Initiated Bernstein Underperform
Feb-22-23 Downgrade Oppenheimer Outperform → Perform
Feb-21-23 Initiated Citigroup Neutral
Jan-30-23 Initiated BMO Capital Markets Market Perform
Jan-18-23 Initiated Canaccord Genuity Hold
Oct-31-22 Upgrade Oppenheimer Perform → Outperform
Jul-13-22 Initiated Cantor Fitzgerald Overweight
Jun-13-22 Resumed Wedbush Neutral
Apr-25-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-22-21 Upgrade William Blair Mkt Perform → Outperform
Oct-07-21 Resumed Jefferies Buy
Sep-09-21 Upgrade Stifel Hold → Buy
Jun-04-21 Resumed Robert W. Baird Outperform
Apr-26-21 Resumed Credit Suisse Outperform
Mar-04-21 Resumed Guggenheim Buy
Mar-01-21 Upgrade Evercore ISI In-line → Outperform
Aug-20-20 Downgrade Citigroup Buy → Neutral
Aug-20-20 Downgrade William Blair Outperform → Mkt Perform
Aug-19-20 Downgrade Evercore ISI Outperform → In-line
Aug-19-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-19-20 Downgrade Stifel Buy → Hold
Jul-08-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-06-20 Reiterated Citigroup Buy
Jan-28-20 Initiated BMO Capital Markets Market Perform
Jan-27-20 Initiated BMO Capital Markets Market Perform
Jan-24-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-27-19 Upgrade Barclays Equal Weight → Overweight
Nov-12-19 Initiated SunTrust Buy
Oct-17-19 Resumed BofA/Merrill Buy
May-23-19 Resumed Citigroup Buy
Apr-09-19 Resumed Raymond James Outperform
Jan-02-19 Downgrade Raymond James Outperform → Mkt Perform
Dec-14-18 Initiated Wolfe Research Outperform
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Aug-07-18 Reiterated Stifel Buy
Aug-03-18 Reiterated Stifel Buy
View All

Biomarin Pharmaceutical Inc Stock (BMRN) Latest News

pulisher
Aug 20, 2025

Will BioMarin Pharmaceutical Inc. Reverse From Oversold ConditionsJuly 2025 Snapshot & Fast Exit Strategy with Risk Control - classian.co.kr

Aug 20, 2025
pulisher
Aug 19, 2025

BioMarin stock price target raised to $95 by Bernstein following Inozyme acquisition - Investing.com

Aug 19, 2025
pulisher
Aug 19, 2025

2 Reasons to Watch BMRN and 1 to Stay Cautious - Yahoo Finance

Aug 19, 2025
pulisher
Aug 19, 2025

Predicting the Next Rule Breaker Buyout - The Motley Fool

Aug 19, 2025
pulisher
Aug 18, 2025

BioMarin (BMRN) Posts Strong Q2 Growth, Advances Rare Disease Research - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance

Aug 18, 2025
pulisher
Aug 16, 2025

Can BioMarin Pharmaceutical Inc. Overcome Bearish SentimentMarket Volume Summary & Long-Term Growth Plans - classian.co.kr

Aug 16, 2025
pulisher
Aug 15, 2025

Trendlines Suggest BioMarin Pharmaceutical Inc. May Bottom Out Soon2025 Big Picture & High Conviction Buy Zone Alerts - kangso.co.kr

Aug 15, 2025
pulisher
Aug 15, 2025

BioMarin Fights Back After NICE Blocks English Funding For £500K Batten Disease Drug - insights.citeline.com

Aug 15, 2025
pulisher
Aug 15, 2025

Trapped Investors in BioMarin Pharmaceutical Inc. Await Breakout Signal2025 Retail Activity & Technical Entry and Exit Alerts - metal.it

Aug 15, 2025
pulisher
Aug 14, 2025

U.S. Batten disease experts who lobbied B.C. to reinstate drug had relationships with company - Times Colonist

Aug 14, 2025
pulisher
Aug 14, 2025

Evaluating BioMarin Pharmaceutical Inc. with trendline analysis2025 Performance Recap & AI Forecast Swing Trade Picks - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Is BioMarin Pharmaceutical Inc. forming a bottoming baseMarket Performance Report & Verified Short-Term Trading Plans - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

BioMarin’s SWOT analysis: rare disease specialist’s stock faces competition, pipeline potential - Investing.com Nigeria

Aug 14, 2025
pulisher
Aug 14, 2025

BioMarin’s SWOT analysis: rare disease specialist’s stock faces competition, pipeline potential By Investing.com - Investing.com South Africa

Aug 14, 2025
pulisher
Aug 14, 2025

What machine learning models say about BioMarin Pharmaceutical Inc.2025 Support & Resistance & Advanced Technical Signal Analysis - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 - MSN

Aug 14, 2025
pulisher
Aug 13, 2025

Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know - Yahoo Finance

Aug 13, 2025
pulisher
Aug 13, 2025

Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know | FinancialContent - FinancialContent

Aug 13, 2025
pulisher
Aug 13, 2025

Is BioMarin Pharmaceutical Inc. stock poised for growthJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance

Aug 13, 2025
pulisher
Aug 13, 2025

Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma - Barchart.com

Aug 13, 2025
pulisher
Aug 13, 2025

BC consulted U.S. Batten disease experts who had links to drug company - Vancouver Sun

Aug 13, 2025
pulisher
Aug 13, 2025

Solid Earnings Reflect BioMarin Pharmaceutical's (NASDAQ:BMRN) Strength As A Business - Yahoo Finance

Aug 13, 2025
pulisher
Aug 13, 2025

Can Traders Expect Breakout From BioMarin Pharmaceutical Inc. This WeekJuly 2025 Setups & Stock Timing and Entry Methods - beatles.ru

Aug 13, 2025
pulisher
Aug 12, 2025

BioMarin Announces Resignation of Chief Accounting Officer - The Globe and Mail

Aug 12, 2025
pulisher
Aug 12, 2025

Skeletal Dysplasia Market Growth Analysis 2025-2030 - GlobeNewswire

Aug 12, 2025
pulisher
Aug 12, 2025

Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Refocused, deal-hungry drugmaker BioMarin pushes toward $4 billion revenue target - The Business Journals

Aug 12, 2025
pulisher
Aug 12, 2025

Blair William & Co. IL Cuts Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

Aug 12, 2025
pulisher
Aug 12, 2025

PNC Financial Services Group Inc. Boosts Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

Aug 12, 2025
pulisher
Aug 11, 2025

Risk vs reward if holding onto BioMarin Pharmaceutical Inc.Market Ready Picks with Technical Support - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

Using portfolio simulators with BioMarin Pharmaceutical Inc. includedFree Capital Protection Trading Strategies - Newser

Aug 11, 2025
pulisher
Aug 10, 2025

What does recent volatility data suggest for BioMarin Pharmaceutical Inc.Machine Learning Stock Movement Detector - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

Will BioMarin Pharmaceutical Inc. Benefit From Broader Market BounceTrade Timing Strategy With Technical Data Explained - beatles.ru

Aug 10, 2025
pulisher
Aug 09, 2025

Using economic indicators to assess BioMarin Pharmaceutical Inc. potentialFree Secure Return Focused Investment Plan - Newser

Aug 09, 2025
pulisher
Aug 08, 2025

The Top 12 Companies Hiring in Biopharma Now - BioSpace

Aug 08, 2025
pulisher
Aug 07, 2025

One Healthcare Stock to Watch: BioMarin Pharmaceutical (BMRN) - AInvest

Aug 07, 2025
pulisher
Aug 06, 2025

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st

Aug 06, 2025
pulisher
Aug 06, 2025

Positive Earnings Growth Hasn't Been Enough to Get BioMarin Pharmaceutical (NASDAQ:BMRN) Shareholders a Favorable Return Over the Last Five Years - 富途牛牛

Aug 06, 2025
pulisher
Aug 06, 2025

BioMarin Pharmaceutical Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Yahoo Finance

Aug 06, 2025
pulisher
Aug 06, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 06, 2025
pulisher
Aug 06, 2025

BioMarin Pharmaceutical (BMRN) Receives a Buy from Stifel Nicolaus - The Globe and Mail

Aug 06, 2025
pulisher
Aug 06, 2025

Biomarin Pharmaceutical shares rise 2.68% premarket after UBS raised its price target to $114. - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results - The Globe and Mail

Aug 06, 2025
pulisher
Aug 05, 2025

Backtesting results for BioMarin Pharmaceutical Inc. trading strategiesFree Daily Momentum Screener With Alerts - Newser

Aug 05, 2025
pulisher
Aug 05, 2025

BioMarin’s Earnings Call: Growth Amid Challenges - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 (NASDAQ:BMRN) - Seeking Alpha

Aug 05, 2025
pulisher
Aug 05, 2025

Research Alert: CFRA Keeps Buy View On Shares Of Biomarin Pharmaceutical Inc. - 富途牛牛

Aug 05, 2025
pulisher
Aug 05, 2025

BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView

Aug 05, 2025

Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):